BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home » Topics » Disease categories and therapies » Ear, nose and throat

Ear, nose and throat
Ear, nose and throat RSS Feed RSS

FDA allows phase III protocol for SPI-1005 for Meniere's disease

June 10, 2020

Otoferlin gene therapy restores hearing in congenital deafness model

May 18, 2020
Propel implant devices

COVID-19 hits Intersect ENT after good start to year

May 12, 2020
By Liz Hollis
Intersect ENT Inc., of Menlo Park, Calif., saw its revenue for the first quarter of 2020 fall to $19.8 million. That figure compares with $26.7 million for the same period last year, with the COVID-19 pandemic having a significant impact on procedures.
Read More

Autifony Therapeutics identifies new K(V)3 potassium channel modulators

April 30, 2020

Fetal pharmacotherapy in the developing inner ear may rescue congenital deafness

April 22, 2020
cochlear-remote-check.png

Amid COVID-19 uncertainty and patent battle loss, Cochlear raises AU$880M, rolls out remote solution

April 21, 2020
By Tamra Sami
PERTH, Australia – Cochlear Ltd., of Sydney, is gearing up to launch its new Remote Check solution for cochlear implant users on the heels of an AU$880 million (US$559 million) capital raise and a patent battle loss that it plans to appeal.
Read More
cochlear-remote-check.png

Amid COVID-19 uncertainty and patent battle loss, Cochlear raises AU$880M, rolls out remote solution

April 15, 2020
By Tamra Sami
PERTH, Australia – Cochlear Ltd., of Sydney, is gearing up to launch its new Remote Check solution for cochlear implant users on the heels of an AU$880 million (US$559 million) capital raise and a patent battle loss that it plans to appeal.
Read More
Product image

Aerin Medical gets FDA nod for procedure for chronic rhinitis

March 6, 2020
By Liz Hollis
Aerin Medical Inc., an Austin, Texas-based company focused on minimally invasive solutions for chronic nasal conditions, has won U.S. FDA clearance for the Rhinaer Stylus to treat chronic rhinitis. The Rhinaer procedure can be performed under a local anesthetic in an ear, nose and throat (ENT) physician’s office, with no incisions and minimal discomfort.
Read More

Novel motheaten spontaneous mutation mouse model of otitis media

Feb. 5, 2020

Gerbil model of cholesteatoma developed to test oncolytic HSV potential

Feb. 4, 2020
Previous 1 2 … 8 9 10 11 12 13 14 15 16 … 25 26 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 11, 2025.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing